References
- Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21(6):525–527. DOI:https://doi.org/10.1136/gut.21.6.525.
- Chang CW, Wong JM, Tung CC, et al. Intestinal stricture in Crohn’s disease. Intest Res. 2015;13(1):19–26. DOI:https://doi.org/10.5217/ir.2015.13.1.19.
- Bermejo F, Garrido E, Chaparro M, et al. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn’s disease: are antibiotics enough? Inflamm Bowel Dis. 2012;18(8):1509–1514.
- Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum. 2001;44(12):2728–2736. DOI:https://doi.org/10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8.
- Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83(7):703–709.
- Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55(5):401–412.
- Eppinga H, Poortinga S, Thio HB, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783–1789. DOI:https://doi.org/10.1097/MIB.0000000000001169.
- Vavricka SR, Scharl M, Gubler M, et al. Biologics for extraintestinal manifestations of IBD. Curr Drug Targets. 2014;15(11):1064–1073. DOI:https://doi.org/10.2174/1389450115666140908125453.
- Shah J, Shah A, Hassman L, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(11):1832–1838. DOI:https://doi.org/10.1093/ibd/izaa359.
- Katsanos KH, Torres J, Roda G, et al. Review article: non-malignant oral manifestations in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(1):40–60. DOI:https://doi.org/10.1111/apt.13217.
- Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151(4):660–669. DOI:https://doi.org/10.1053/j.gastro.2016.06.021.
- Schwartz DA, Tagarro I, Carmen Díez M, et al. Prevalence of fistulizing Crohn’s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25(11):1773–1779. DOI:https://doi.org/10.1093/ibd/izz056.
- Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25(6):1054–1060. DOI:https://doi.org/10.1093/ibd/izy329.
- Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing crohn’s disease: the Toronto consensus. J Can Assoc Gastroenterol. 2018;1(4):141–154. DOI:https://doi.org/10.1093/jcag/gwy047.
- Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–1392. DOI:https://doi.org/10.1136/gutjnl-2013-306709.
- Feroz SH, Ahmed A, Muralidharan A, et al. Comparison of the efficacy of the various treatment modalities in the management of perianal Crohn’s fistula: a review. Cureus. 2020;12(12):e11882.
- Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–1405. DOI:https://doi.org/10.1056/NEJM199905063401804.
- Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885. DOI:https://doi.org/10.1056/NEJMoa030815.
- Bouguen G, Huguet A, Amiot A, et al. Efficacy and safety of tumor necrosis factor antagonists in treatment of internal fistulizing Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(3):628–636. DOI:https://doi.org/10.1016/j.cgh.2019.05.027.
- Singh S, Proctor D, Scott FI, et al. AGA Technical Review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2512–2556. DOI:https://doi.org/10.1053/j.gastro.2021.04.023.
- West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11–12):1329–1336. DOI:https://doi.org/10.1111/j.1365-2036.2004.02247.x.
- Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58(7):940–948. DOI:https://doi.org/10.1136/gut.2008.159251.
- Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333. DOI:https://doi.org/10.1053/j.gastro.2005.11.030.
- Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–838. DOI:https://doi.org/10.7326/0003-4819-146-12-200706190-00159.
- Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32(10):1228–1239. DOI:https://doi.org/10.1111/j.1365-2036.2010.04466.x.
- Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–299. DOI:https://doi.org/10.1136/gutjnl-2013-304488.
- Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56:53–58. DOI:https://doi.org/10.1080/00365521.2020.1854848.
- Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn’s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14(1):33–45. DOI:https://doi.org/10.1093/ecco-jcc/jjz119.
- Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn’s disease: the BioLAP multicenter study from the GETAID. Am J Gastroenterol. 2020;115(11):1812–1820. DOI:https://doi.org/10.14309/ajg.0000000000000810.
- Lee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892. DOI:https://doi.org/10.1016/j.cgh.2018.01.030.
- Plevris N, Fulforth J, Siakavellas S, et al. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn’s disease: the Scottish ustekinumab cohort. J Gastroenterol Hepatol. 2021;36(8):2067–2075. DOI:https://doi.org/10.1111/jgh.15390.
- Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–1243. DOI:https://doi.org/10.1111/apt.14016.
- Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–1669. DOI:https://doi.org/10.1097/MIB.0000000000000842.
- Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12(5):621–626. DOI:https://doi.org/10.1093/ecco-jcc/jjy019.
- Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51(7):719–727. DOI:https://doi.org/10.1111/apt.15665.
- Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE study. Clin Gastroenterol Hepatol. 2021 Sep 29;S1542-3565(21):01042–9. DOI:https://doi.org/10.1016/j.cgh.2021.09.028.
- Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2017;153(1):59–62. DOI:https://doi.org/10.1053/j.gastro.2017.04.001.
- Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2019;156(8):2208–2216. DOI:https://doi.org/10.1053/j.gastro.2019.02.005.
- Zhou C, Li M, Zhang Y, et al. Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial. Stem Cell Res Ther. 2020;11(1):124. DOI:https://doi.org/10.1186/s13287-020-01636-4.
- Wainstein C, Quera R, Fluxá D, et al. Stem cell therapy in refractory perineal Crohn’s disease: long-term follow-up. Colorectal Dis. 2018 Jan 6;20(3):O68–O75. Online ahead of print. DOI:https://doi.org/10.1111/codi.14002.
- Park KJ, Ryoo SB, Kim JS, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn’s disease: a pilot clinical trial. Colorectal Dis. 2016;18(5):468–476. DOI:https://doi.org/10.1111/codi.13223.
- Nikolic M, Stift A, Reinisch W, et al. Allogeneic expanded adipose-derived stem cells in the treatment of rectovaginal fistulas in Crohn’s disease. Colorectal Dis. 2021;23(1):153–158. DOI:https://doi.org/10.1111/codi.15324.
- Lightner AL, Dozois EJ, Dietz AB, et al. Matrix-delivered autologous mesenchymal stem cell therapy for refractory rectovaginal crohn’s fistulas. Inflamm Bowel Dis. 2020;26(5):670–677. DOI:https://doi.org/10.1093/ibd/izz215.
- Knyazev OV, Fadeeva NA, Kagramanova AV, et al. Stem cell therapy for perianal Crohn’s disease. Ter Arkh. 2018;90(3):60–66.
- Herreros MD, Garcia-Olmo D, Guadalajara H, et al. Stem cell therapy: a compassionate use program in perianal fistula. Stem Cells Int. 2019;2019:6132340.
- Garcia-Olmo D, Guadalajara H, Rubio-Perez I, et al. Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol. 2015;21(11):3330–3336. DOI:https://doi.org/10.3748/wjg.v21.i11.3330.
- García-Arranz M, Herreros MD, González-Gómez C, et al. treatment of Crohn’s-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Transl Med. 2016;5(11):1441–1446. DOI:https://doi.org/10.5966/sctm.2015-0356.
- Ciccocioppo R, Gallia A, Sgarella A, et al. Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. Mayo Clin Proc. 2015;90(6):747–755. DOI:https://doi.org/10.1016/j.mayocp.2015.03.023.
- Cho YB, Park KJ, Yoon SN, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4(5):532–537. DOI:https://doi.org/10.5966/sctm.2014-0199.
- Laureti S, Gionchetti P, Cappelli A, et al. Refractory complex crohn’s perianal fistulas: a role for autologous microfragmented adipose tissue injection. Inflamm Bowel Dis. 2020;26(2):321–330. DOI:https://doi.org/10.1093/ibd/izz051.
- Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918–927. DOI:https://doi.org/10.1053/j.gastro.2015.06.014.
- Barnhoorn MC, Wasser MNJM, Roelofs H, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn’s disease perianal fistulas. J Crohns Colitis. 2020;14(1):64–70. DOI:https://doi.org/10.1093/ecco-jcc/jjz116.
- Scott LJ. Darvadstrocel: a review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs. 2018;32(6):627–634.
- Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–1290. DOI:https://doi.org/10.1016/S0140-6736(16)31203-X.
- Panés J, García-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018;154(5):1334–1342. DOI:https://doi.org/10.1053/j.gastro.2017.12.020.
- Ko JZ, Johnson S, Dave M. Efficacy and safety of mesenchymal stem/stromal cell therapy for inflammatory bowel diseases: an up-to-date systematic review. Biomolecules. 2021;11(1):82.
- Rieder F, Latella G, Magro F, et al. European Crohn’s and colitis organization topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J Crohns Colitis. 2016;10(8):873–885. DOI:https://doi.org/10.1093/ecco-jcc/jjw055.
- Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis. 2005;20(1):1–8.
- Samimi R, Flasar MH, Kavic S, et al. Outcome of medical treatment of stricturing and penetrating Crohn’s disease: a retrospective study. Inflamm Bowel Dis. 2010;16(7):1187–1194. DOI:https://doi.org/10.1002/ibd.21160.
- Bouguen G, Trouilloud I, Siproudhis L, et al. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Ther. 2009;30(7):749–756. DOI:https://doi.org/10.1111/j.1365-2036.2009.04089.x.
- Rodríguez-Lago I, Gisbert JP. The role of immunomodulators and biologics in the medical management of stricturing Crohn’s disease. J Crohns Colitis. 2020;14(4):557–566.
- Pallotta N, Barberani F, Hassan NA, et al. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14(12):1885–1890. DOI:https://doi.org/10.3748/wjg.14.1885.
- Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42(8):977–989. DOI:https://doi.org/10.1111/apt.13363.
- Allocca M, Bonifacio C, Fiorino G, et al. Efficacy of tumour necrosis factor antagonists in stricturing Crohn’s disease: a tertiary center real-life experience. Dig Liver Dis. 2017;49(8):872–877. DOI:https://doi.org/10.1016/j.dld.2017.03.012.
- Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67(1):53–60. DOI:https://doi.org/10.1136/gutjnl-2016-312581.
- Steiner CA, Rodansky ES, Johnson LA, et al. AXL is a potential target for the treatment of intestinal fibrosis. Inflamm Bowel Dis. 2021;27(3):303–316. DOI:https://doi.org/10.1093/ibd/izaa169.
- Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39(5):441–448. DOI:https://doi.org/10.1007/s00535-003-1317-2.
- Sahai A, Bélair M, Gianfelice D, et al. Percutaneous drainage of intra-abdominal abscesses in Crohn’s disease: short and long-term outcome. Am J Gastroenterol. 1997;92(2):275–278.
- Neufeld D, Keidar A, Gutman M, et al. Abdominal wall abscesses in patients with Crohn’s disease: clinical outcome. J Gastrointest Surg. 2006;10(3):445–449. DOI:https://doi.org/10.1016/j.gassur.2005.06.004.
- Garcia JC, Persky SE, Bonis PA, et al. Abscesses in Crohn’s disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001;32(5):409–412. DOI:https://doi.org/10.1097/00004836-200105000-00010.
- Cullen G, Vaughn B, Ahmed A, et al. Abdominal phlegmons in Crohn’s disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis. 2012;18(4):691–696. DOI:https://doi.org/10.1002/ibd.21783.
- Nguyen DL, Sandborn WJ, EV L Jr, et al. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2012;10(4):400–404. DOI:https://doi.org/10.1016/j.cgh.2011.11.023.
- Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127–1136. DOI:https://doi.org/10.1111/j.1365-2036.2006.02878.x.
- Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–1992. DOI:https://doi.org/10.1097/MIB.0000000000000392.
- Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25(6):406–410. DOI:https://doi.org/10.1007/s00296-004-0467-8.
- Juillerat P, Manz M, Sauter B, et al. Therapies in inflammatory bowel disease patients with extraintestinal manifestations. Digestion. 2020;101(Suppl 1):83–97. DOI:https://doi.org/10.1159/000502816.
- Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 15(1): 25–36. 2017. . https://doi.org/10.1016/j.cgh.2016.06.025.
- Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007;10(3):178–184.
- Greuter T, Rieder F, Kucharzik T, et al. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021;70(4):796–802. DOI:https://doi.org/10.1136/gutjnl-2020-322129.
- Liefferinckx C, Verstockt B, Gils A, et al. Long-term clinical effectiveness of ustekinumab in patients with crohn’s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13(11):1401–1409. DOI:https://doi.org/10.1093/ecco-jcc/jjz080.
- Guillo L, D’Amico F, Danese S, et al. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohns Colitis. 15(7): 1236–1243. 2021. . https://doi.org/10.1093/ecco-jcc/jjaa260.
- Ramos GP, Dimopoulos C, McDonald NM, et al. The Impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: a multicenter study. Inflamm Bowel Dis. 27(8): 1270–1276. 2021. . https://doi.org/10.1093/ibd/izaa293.
- Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47(4):485–493. DOI:https://doi.org/10.1111/apt.14419.
- Rubin D, Reinisch W, Greuter T, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. DOI:https://doi.org/10.1177/17562848211005708
- Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110–119. DOI:https://doi.org/10.1038/ajg.2010.343.
- Jacobi A, Debus D, Schuler G, et al. Infliximab in a patient with refractory mucosal aphthosis. J Eur Acad Dermatol Venereol. 2008;22(1):109–110.
- Jansen FM, Vavricka SR, den Broeder AA, et al. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. United European Gastroenterol J. 2020;8(9):1031–1044. DOI:https://doi.org/10.1177/2050640620958902.
- Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; (4):CD005468. DOI:https://doi.org/10.1002/14651858.CD005468.pub2.
- Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. Bmj. 2020;372:m4447.
- Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016;12(5):282–295.
- Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46(3):755–765. DOI:https://doi.org/10.1002/art.511.
- Van den Bosch F, Kruithof E, De Vos M, et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356(9244):1821–1822. DOI:https://doi.org/10.1016/S0140-6736(00)03239-6.
- Ellman MH, Hanauer S, Sitrin M, et al. Crohn’s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol. 2001;7(2):67–71.
- Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol. 2002;97(10):2688–2690. DOI:https://doi.org/10.1111/j.1572-0241.2002.06064.x.
- Vavricka SR, Gubler M, Gantenbein C, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis. 2017;23(7):1174–1181. DOI:https://doi.org/10.1097/MIB.0000000000001109.
- Feagan BG, Sandborn WJ, Colombel JF, et al. Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13(1):50–57. DOI:https://doi.org/10.1093/ecco-jcc/jjy125.
- Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130–138. DOI:https://doi.org/10.1016/j.cgh.2018.05.026.
- Chateau T, Bonovas S, Le Berre C, et al. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review. J Crohns Colitis. 13(12): 1569–1577. 2019. https://doi.org/10.1093/ecco-jcc/jjz095.
- Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386. DOI:https://doi.org/10.1056/NEJMoa1310476.
- van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347. DOI:https://doi.org/10.1136/annrheumdis-2016-210322.
- Wang W, Cleveland NK, Ollech J, et al. Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis. ACG Case Rep J. 2019;6(9):e00226.
- Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials. Z Rheumatol. 2020 Dec 18. doi:https://doi.org/10.1007/s00393-020-00948-3. Online ahead of print.
- Misselwitz B, Juillerat P, Sulz MC, et al. Emerging treatment options in inflammatory bowel disease: janus kinases, stem cells, and more. Digestion. 2020;101(Suppl 1):69–82. DOI:https://doi.org/10.1159/000507782.
- Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2007;21(3):408–410. DOI:https://doi.org/10.1111/j.1468-3083.2006.01893.x.
- Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn’s disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol. 2008;5(5):278–281.
- Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31(6):823–824.
- Argüelles-Arias F, Castro-Laria L, Lobatón T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949–1954. DOI:https://doi.org/10.1007/s10620-013-2762-2.
- Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases. J Clin Med. 2021;10(2):364. DOI:https://doi.org/10.3390/jcm10020364.
- Diotallevi F, Campanati A, Radi G, et al. Pyoderma gangrenosum successfully treated with golimumab: case report and review of the literature. Dermatol Ther. 2019;32(4):e12928. DOI:https://doi.org/10.1111/dth.12928.
- Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98(8):1821–1826.
- Hayashi H, Kuwabara C, Tarumi K, et al. Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease. J Dermatol. 2012;39(6):576–578. DOI:https://doi.org/10.1111/j.1346-8138.2011.01346.x.
- Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2020;37(9):1108–1110. DOI:https://doi.org/10.1080/003655202320378338.
- Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–509. DOI:https://doi.org/10.1136/gut.2005.074815.
- Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–795. DOI:https://doi.org/10.1038/ajg.2012.42.
- Nunes G, Patita M, Fernandes V. Refractory pyoderma gangrenosum in a patient with Crohn’s disease: complete response to ustekinumab. J Crohns Colitis. 2019;13(6):812–813.
- Phillips FM, Verstockt B, Sebastian S, et al. Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series. J Crohns Colitis. 2020;14(10):1488–1493. DOI:https://doi.org/10.1093/ecco-jcc/jjaa078.
- Spagnuolo R, Dastoli S, Silvestri M, et al. Anti-interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: a case report. Dermatol Ther. 2019;32(2):e12811. DOI:https://doi.org/10.1111/dth.12811.
- Gregory MH, Ciorba MA, Deepak P, et al. Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis. 2019;25(7):e87–e88. DOI:https://doi.org/10.1093/ibd/izz015.
- Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021;46(6):1082–1085. DOI:https://doi.org/10.1111/ced.14683.
- Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn’s disease. Gut. 1968;9(1):17–21.
- Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol. 1990;85(8):962–963.
- Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a danish nationwide cohort study. Br J Dermatol. 2016;175(3):487–492. DOI:https://doi.org/10.1111/bjd.14528.
- Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417–1423.
- Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383–394. DOI:https://doi.org/10.1016/j.jaad.2017.06.043.
- Chen YC, Huang YT, Yang CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS One. 2020;15(12):e0244620. DOI:https://doi.org/10.1371/journal.pone.0244620.
- Egeberg A, Thyssen JP, Burisch J, et al. Incidence and risk of inflammatory bowel disease in patients with psoriasis-a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316–323. DOI:https://doi.org/10.1016/j.jid.2018.07.029.
- Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–436. DOI:https://doi.org/10.1001/archdermatol.2010.384.
- Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet. 2008;371(9625):1675–1684. DOI:https://doi.org/10.1016/S0140-6736(08)60726-6.
- Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542. DOI:https://doi.org/10.1016/j.jaad.2004.02.021.
- Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–1334. DOI:https://doi.org/10.1111/bjd.12404.
- Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2005;165(5):1109–1117. DOI:https://doi.org/10.1111/j.1365-2133.2011.10615.x.
- Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566. DOI:https://doi.org/10.1111/j.1365-2133.2007.08315.x.
- Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115. DOI:https://doi.org/10.1016/j.jaad.2007.09.010.
- Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. DOI:https://doi.org/10.1016/j.jaad.2006.05.027.
- Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314. DOI:https://doi.org/10.1016/j.jaad.2018.04.012.
- Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266–276. DOI:https://doi.org/10.1016/j.jaad.2018.04.013.
- Mease P, Elaine Husni M, Chakravarty SD, et al. Evaluation of improvement in skin and nail psoriasis in bio-naïve patients with active psoriatic arthritis treated with golimumab: results through week 52 of the GO-VIBRANT study. ACR Open Rheumatol. 2020;2(11):640–647. DOI:https://doi.org/10.1002/acr2.11180.
- Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. DOI:https://doi.org/10.1001/jamadermatol.2019.4029.
- Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157. DOI:https://doi.org/10.1136/ard.2004.032268.
- Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–1236. DOI:https://doi.org/10.1002/art.20967.
- Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35(5):869–876.
- Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of Adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040–1050.
- Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476–488. DOI:https://doi.org/10.1002/art.22379.
- Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–1043. DOI:https://doi.org/10.1136/ard.2005.045658.
- Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289. DOI:https://doi.org/10.1002/art.21306.
- Mease PJ, Signorovitch J, Yu AP, et al. Impact of Adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology. 2010;220(1):1–7. DOI:https://doi.org/10.1159/000260371.
- Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69(2):394–399. DOI:https://doi.org/10.1136/ard.2009.111856.
- Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020;6(1):e001117. DOI:https://doi.org/10.1136/rmdopen-2019-001117.
- Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7(7):517–524. DOI:https://doi.org/10.1016/j.crohns.2012.08.007.
- Vedak P, Kroshinsky D, St John J, et al. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697–704. DOI:https://doi.org/10.1111/apt.13542.
- Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–1327.
- Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–1055. DOI:https://doi.org/10.1016/j.cgh.2010.07.022.
- Conforti C, Dianzani C, Zalaudek I, et al. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. J Dermatolog Treat. 2020;22:1–8.
- Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006. DOI:https://doi.org/10.1136/annrheumdis-2013-204741.
- Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016;75(11):1984–1988. DOI:https://doi.org/10.1136/annrheumdis-2015-209068.
- Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–872. DOI:https://doi.org/10.1111/j.1365-2133.2012.10901.x.
- Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–592. DOI:https://doi.org/10.1056/NEJMoa062382.
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789. DOI:https://doi.org/10.1016/S0140-6736(13)60594-2.
- Leonardi CL, Kimball AB, Papp KA, et al. Phoenix 1 study investigators. efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 1). Lancet. 2008;371(9625):1665–1674. DOI:https://doi.org/10.1016/S0140-6736(08)60725-4.
- Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192.
- Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. Dig Liver Dis. 2019;51(7):972–977. DOI:https://doi.org/10.1016/j.dld.2019.03.007.
- Chu DH, Van Voorhees AS, Rosenbach M. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol. 2011;147(10):1228–1230.
- Puig L, Morales-Múnera CE, López-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology. 2012;225(1):14–17. DOI:https://doi.org/10.1159/000339864.
- Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1395–1406. DOI:https://doi.org/10.1111/bjd.13551.
- Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561. DOI:https://doi.org/10.1016/S0140-6736(14)62113-9.
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961. DOI:https://doi.org/10.1111/bjd.14018.
- Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536. DOI:https://doi.org/10.1056/NEJMoa1615977.
- Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550. DOI:https://doi.org/10.1056/NEJMoa1615975.
- Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. DOI:https://doi.org/10.1016/S0140-6736(21)00184-7.
- Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–680. DOI:https://doi.org/10.1016/S2468-1253(18)30233-4.
- Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709. DOI:https://doi.org/10.1016/S0140-6736(17)30570-6.
- LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017 Mar;13(3):181–188.
- Fries W, Giofré MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97(2):499–500.
- Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912. DOI:https://doi.org/10.1001/archopht.123.7.903.
- Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn’s disease. J Crohns Colitis. 2020;14(4):571.
- Pepple KL, Lin P. Targeting interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018;125(12):1977–1983.
- Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53–55.
- Bens G, Laharie D, Beylot-Barry M, et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn’s disease. Br J Dermatol. 2003;149(1):181–184. DOI:https://doi.org/10.1046/j.1365-2133.2003.05385.x.
- Staines KS, Green R, Felix DH. The management of fistulizing oral Crohn’s disease with infliximab. J Oral Pathol Med. 2007;36(7):444–446.
- Cardoso H, Nunes AC, Carneiro F, et al. Successful infliximab therapy for oral Crohn’s disease. Inflamm Bowel Dis. 2006;12(4):337–338. DOI:https://doi.org/10.1097/01.MIB.0000215096.51943.82.
- Mijandrusić-Sincić B, Licul V, Gorup L, et al. Pyostomatitis vegetans associated with inflammatory bowel disease–report of two cases. Coll Antropol. 2010;34(Suppl 2):279–282.
- Sánchez AR, Rogers RS 3rd, Sheridan PJ. Oral ulcerations are associated with the loss of response to infliximab in Crohn’s disease. J Oral Pathol Med. 2005;34(1):53–55.
- Mertz A, Nguyen NA, Katsanos KH, et al. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019;32(2):124–133. DOI:https://doi.org/10.20524/aog.2019.0344.
- Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522–526. DOI:https://doi.org/10.1097/MCG.0b013e3181662426.
- Duca I, Ramírez de la Piscina P, Estrada S, et al. Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. World J Gastroenterol. 2013;19(4):590–593. DOI:https://doi.org/10.3748/wjg.v19.i4.590.
- Caron B, Peyrin-Biroulet L, Pariente B, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study. J Crohns Colitis. 2019;13(10):1239–1247. DOI:https://doi.org/10.1093/ecco-jcc/jjz088.
- Christensen B, Colman RJ, Micic D, et al. Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety. Inflamm Bowel Dis. 2018;24(4):849–860. DOI:https://doi.org/10.1093/ibd/izx067.
- Tse CS, EV L Jr, Raffals LE, et al. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(2):190–195. DOI:https://doi.org/10.1111/apt.14829.
- Lynch KD, Chapman RW, Keshav S, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(1):179–187. DOI:https://doi.org/10.1016/j.cgh.2019.05.013.